Aeras Global TB Vaccine Foundation
Programs and results
What we aim to solve
Our programs
What are the organization's current programs, how do they measure success, and who do the programs serve?
Development of new recombinant live BCG vaccine candidates
Recombinant BCG (rBCG) strains are being constructed with enhanced immunogenicity based on the capacity to escape the endosome and the overexpression of select tuberculosis antigens. The lead candidate, AERAS-406 also includes a pro-apoptotic factor. The TB antigens 85A, 85B, 10 4, RV3407, AERAS-407 is in pre-clinical development.
Where we work
This profile needs more info.
If it is your nonprofit, add geographic service areas to create a map on your profile.
Login and updateExternal reviews

Photos
Goals & Strategy
Learn about the organization's key goals, strategies, capabilities, and progress.
Charting impact
Four powerful questions that require reflection about what really matters - results.
What is the organization aiming to accomplish?
The overall goal of Aeras is to markedly lower tuberculosis incidence and prevalence through vaccination. This goal can likely best be achieved by developing a portfolio of vaccines that protect individuals from infection, prevent infected individuals from progressing to active disease, and decrease the transmission capacity of those with active disease. Aeras has outlined four primary goals for 2012-2016: 1)Complete clinical trials of current candidates; 2) Build a robust and diverse pipeline of new TB vaccine candidates; 3) refine TB vaccine candidate selection and advancement; and 4) Strengthen and diversify the funding base by building new collaborations and partnerships that advance tuberculosis vaccine development.
What are the organization's key strategies for making this happen?
Aeras operates on a partnership model and supports the development of the world’s most promising TB vaccine candidates by working in collaboration with a diverse global community of scientists and researchers from academia, industry, governments and funders.
What are the organization's capabilities for doing this?
With world-class in-house capacity in preclinical research, immunology, regulatory affairs, clinical development and vaccine manufacturing, Aeras is uniquely qualified to serve as a critical translational bridge from research to licensure and from the laboratory to manufacturing.
What have they accomplished so far and what's next?
Aeras and its partners have six TB vaccines undergoing clinical testing and there is a robust pipeline of early stage candidates in the pipeline being evaluated against globally agreed upon stringent scientific criteria for advancement. Aeras and its partners published a framework for TB vaccine development for the next 10 years in March 2012. In February 2012, Aeras and its partners published findings from a major TB vaccine clinical trial. While the trial proved the vaccine to be not effective in preventing TB in infants, it added significanlty to the body of knowledge on TB vaccine and its findings are being applied to other candidates in development.
Financials
Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more
about GuideStar Pro.
Operations
The people, governance practices, and partners that make the organization tick.
Connect with nonprofit leaders
SubscribeBuild relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.
Connect with nonprofit leaders
SubscribeBuild relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.
Aeras Global TB Vaccine Foundation
Board of directorsas of 11/12/2013
R. Douglas
No affiliation
Peter Barton Hutt
Covington & Burling
R. Gordon Douglas
No Affiliation
Hoosen Coovadia
University of the Witwatersrand and University of KwaZulu-Natal
Regina Rabinovich
Harvard School of Public Health
Jim Connolly
Aeras
Barry Bloom
Harvard University
Marja Esveld
Netherlands Ministry of Health
Gustavo Gonzalez-Canali
Medecin des Hôpitaux
Wayne Pisano
Gerd Zettlmeissl
Intercell AG
Lota Zoth
MedImmune, Inc.